CSL Behring
Search results
CSL. Always Evolving for a Better World. CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need.
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double ...
Benzinga via Yahoo
8 hours ago
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine ...
Benzinga via Yahoo
4 days ago
CSL Limited was incorporated in 1991 and listed on the Australian Securities Exchange (ASX) in 1994. Today, CSL comprises businesses with longstanding, specialized expertise: CSL Behring, a global leader in rare and serious diseases; its subsidiary CSL Plasma, which operates one of the world’s largest plasma collection networks;
2024 Full Year Financial Results. We have announced our 2024 Full Year Financial Results for the period ending June 30 th 2024. Please click here to view the full information. A recording of the 2024 Full Year Results Announcement Webcast can be viewed here.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
Today, with the combined expertise of CSL Behring (with oversight to CSL Plasma), CSL Seqirus, and CSL Vifor—and our singular commitment to relentlessly innovate—CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they deserve.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry. CSL Behring: Rare & Serious Diseases Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine companies.
5 days ago · CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have... May 30, 2024
Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people.
CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration.
New and exciting opportunities allow us to address previously unmet patient needs and these continue to drive us each day. In addition, CSL continues to build on its capabilities across the R&D value chain, from discovery research to pharmacovigilance to its currently marketed therapies.
